How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
57
ARKG Quote, Financials, Valuation and Earnings
Last price:
$30.42
Seasonality move
:
-3.83%
Day range:
$30.26 - $31.37
52-week range:
$17.51 - $34.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
4.1M
Avg. volume:
2.6M
1-year change:
11.55%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
$30.43 | -- | -- | -- | $0.00 | 0% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$40.84 | -- | -- | -- | $0.66 | 1.61% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$47.69 | -- | -- | -- | $0.59 | 1.31% | -- |
|
IBB
iShares Biotechnology ETF
|
$172.43 | -- | -- | -- | $0.18 | 0.23% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$81.87 | -- | -- | -- | $0.42 | 1% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$124.75 | -- | -- | -- | $0.41 | 0.36% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | 2.471 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.354 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.683 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 0.638 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.675 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 0.938 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
ARK Genomic Revolution ETF vs. Competitors
-
Which has Higher Returns ARKG or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About ARKG or BBC?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is ARKG or BBC More Risky?
ARK Genomic Revolution ETF has a beta of 1.763, which suggesting that the stock is 76.286% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.512%.
-
Which is a Better Dividend Stock ARKG or BBC?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.61% to investors and pays a quarterly dividend of $0.66 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or BBC?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns ARKG or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or GNOM?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is ARKG or GNOM More Risky?
ARK Genomic Revolution ETF has a beta of 1.763, which suggesting that the stock is 76.286% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.257, suggesting its more volatile than the S&P 500 by 25.707%.
-
Which is a Better Dividend Stock ARKG or GNOM?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Genomics & Biotechnology ETF offers a yield of 1.31% to investors and pays a quarterly dividend of $0.59 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or GNOM?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or IBB?
iShares Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or IBB?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than iShares Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is ARKG or IBB More Risky?
ARK Genomic Revolution ETF has a beta of 1.763, which suggesting that the stock is 76.286% more volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.167%.
-
Which is a Better Dividend Stock ARKG or IBB?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares Biotechnology ETF offers a yield of 0.23% to investors and pays a quarterly dividend of $0.18 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or IBB?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About ARKG or PBE?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is ARKG or PBE More Risky?
ARK Genomic Revolution ETF has a beta of 1.763, which suggesting that the stock is 76.286% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.831%.
-
Which is a Better Dividend Stock ARKG or PBE?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 1% to investors and pays a quarterly dividend of $0.42 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or PBE?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns ARKG or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About ARKG or XBI?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe ARK Genomic Revolution ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is ARKG or XBI More Risky?
ARK Genomic Revolution ETF has a beta of 1.763, which suggesting that the stock is 76.286% more volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.765%.
-
Which is a Better Dividend Stock ARKG or XBI?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. State Street SPDR S&P Biotech ETF offers a yield of 0.36% to investors and pays a quarterly dividend of $0.41 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or XBI?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
